UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Therapeutic drug monitoring of oral targeted antineoplastic drugs

European journal of clinical pharmacology, 2021-04, Vol.77 (4), p.441-464

2021

Volltextzugriff (PDF)

The mutational footprints of cancer therapies

Nature genetics, 2019-12, Vol.51 (12), p.1732-1740

2019

Volltextzugriff (PDF)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

The New England journal of medicine, 2019-10, Vol.381 (17), p.1632-1643

2019

Volltextzugriff (PDF)

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Clinical pharmacology and therapeutics, 2017-11, Vol.102 (5), p.765-776

2017

Volltextzugriff (PDF)

Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features

Nature communications, 2021-01, Vol.12 (1), p.574-574, Article 574

2021

Volltextzugriff (PDF)

Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Clinical cancer research, 2023-01, Vol.29 (1), p.110-121

2023

Volltextzugriff (PDF)

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

Clinical pharmacokinetics, 2014-04, Vol.53 (4), p.305-325

2014

Volltextzugriff (PDF)

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine

European journal of clinical pharmacology, 2019-09, Vol.75 (9), p.1309-1318

2019

Volltextzugriff (PDF)

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

Nature communications, 2019-11, Vol.10 (1), p.5251-13, Article 5251

2019

Volltextzugriff (PDF)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose

British journal of clinical pharmacology, 2020-02, Vol.86 (2), p.258-273

2020

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing

Clinical pharmacokinetics, 2017-09, Vol.56 (9), p.987-997

2017

Volltextzugriff (PDF)

Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites

Therapeutic drug monitoring, 2024-08

2024

Volltextzugriff (PDF)

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

British journal of cancer, 2022-04, Vol.126 (7), p.1010-1017

2022

Volltextzugriff (PDF)

Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

Pharmaceutical research, 2022-10, Vol.39 (10), p.2507-2514

2022

Volltextzugriff (PDF)

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

Clinical cancer research, 2016-12, Vol.22 (23), p.5738-5746

2016

Volltextzugriff (PDF)

Author Correction: Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features

Nature communications, 2021-05, Vol.12 (1), p.3269-3269, Article 3269

2021

Volltextzugriff (PDF)

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib

Pharmaceutical research, 2022-04, Vol.39 (4), p.669-676

2022

Volltextzugriff (PDF)

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?

Frontiers in oncology, 2022-09, Vol.12, p.940582-940582

2022

Volltextzugriff (PDF)

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients

Therapeutic drug monitoring, 2024-02, Vol.46 (1), p.73-79

2024

Volltextzugriff (PDF)

Solubility and bioavailability improvement of pazopanib hydrochloride

International journal of pharmaceutics, 2018-06, Vol.544 (1), p.181-190

2018

Volltextzugriff (PDF)

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Nature communications, 2024-05, Vol.15 (1), p.4091-14, Article 4091

2024

Volltextzugriff (PDF)

Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology

Clinical pharmacology and therapeutics, 2020-09, Vol.108 (3), p.494-505

2020

Volltextzugriff (PDF)

Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer

BMC cancer, 2022-03, Vol.22 (1), p.228-228, Article 228

2022

Volltextzugriff (PDF)

Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical Challenges

Cancers, 2023-06, Vol.15 (13), p.3293

2023

Volltextzugriff (PDF)

1 – 25 von 214

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieEuropean Journal Of Cancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(208)
Mit Volltextzugriff
(187)

Publikationsform

Artikel
(214)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Therapeutic drug monitoring of oral targeted antineoplastic drugs

The mutational footprints of cancer therapies

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features

Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing

Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

Author Correction: Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients

Solubility and bioavailability improvement of pazopanib hydrochloride

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology

Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer

Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material

Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical Challenges

Aktive Filter

Suchergebnisse filtern